These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 24627588)

  • 1. Hepatic inflammation and progressive liver fibrosis in chronic liver disease.
    Czaja AJ
    World J Gastroenterol; 2014 Mar; 20(10):2515-32. PubMed ID: 24627588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.
    Tanwar S; Rhodes F; Srivastava A; Trembling PM; Rosenberg WM
    World J Gastroenterol; 2020 Jan; 26(2):109-133. PubMed ID: 31969775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management strategies for liver fibrosis.
    Altamirano-Barrera A; Barranco-Fragoso B; Méndez-Sánchez N
    Ann Hepatol; 2017; 16(1):48-56. PubMed ID: 28051792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C.
    Baroni GS; Pastorelli A; Manzin A; Benedetti A; Marucci L; Solforosi L; Di Sario A; Brunelli E; Orlandi F; Clementi M; Macarri G
    Liver; 1999 Jun; 19(3):212-9. PubMed ID: 10395041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis.
    D'Ambrosio R; Aghemo A; Rumi MG; Ronchi G; Donato MF; Paradis V; Colombo M; Bedossa P
    Hepatology; 2012 Aug; 56(2):532-43. PubMed ID: 22271347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases.
    Yamaguchi T; Yoshida K; Murata M; Matsuzaki K
    World J Gastroenterol; 2014 Sep; 20(35):12381-90. PubMed ID: 25253939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy.
    Li H; Huang MH; Jiang JD; Peng ZG
    World J Gastroenterol; 2018 Dec; 24(47):5297-5311. PubMed ID: 30598575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease.
    Vespasiani-Gentilucci U; Carotti S; Onetti-Muda A; Perrone G; Ginanni-Corradini S; Latasa MU; Avila MA; Carpino G; Picardi A; Morini S
    Mod Pathol; 2012 Apr; 25(4):576-89. PubMed ID: 22173288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chance of hepatic fibrosis treatment in chronic hepatitis C].
    Flisiak R
    Przegl Epidemiol; 2004; 58 Suppl 1():76-9. PubMed ID: 15807162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
    Morishima C; Shiffman ML; Dienstag JL; Lindsay KL; Szabo G; Everson GT; Lok AS; Di Bisceglie AM; Ghany MG; Naishadham D; Morgan TR; Wright EC;
    Am J Gastroenterol; 2012 Sep; 107(9):1388-98. PubMed ID: 22688849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
    Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A
    World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.
    Czaja AJ
    Aliment Pharmacol Ther; 2014 Feb; 39(4):385-406. PubMed ID: 24387318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired CD4⁺ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients.
    Glässner A; Eisenhardt M; Kokordelis P; Krämer B; Wolter F; Nischalke HD; Boesecke C; Sauerbruch T; Rockstroh JK; Spengler U; Nattermann J
    J Hepatol; 2013 Sep; 59(3):427-33. PubMed ID: 23665286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory status in human hepatic cirrhosis.
    Martínez-Esparza M; Tristán-Manzano M; Ruiz-Alcaraz AJ; García-Peñarrubia P
    World J Gastroenterol; 2015 Nov; 21(41):11522-41. PubMed ID: 26556984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk network among multiple inflammatory mediators in liver fibrosis.
    Zhangdi HJ; Su SB; Wang F; Liang ZY; Yan YD; Qin SY; Jiang HX
    World J Gastroenterol; 2019 Sep; 25(33):4835-4849. PubMed ID: 31543677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    Gao Y; Ren H; Meng F; Li J; Cheung E; Li H; Zhao J; Liu H; Liu Z; Zhang M
    PLoS One; 2016; 11(4):e0154419. PubMed ID: 27123854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.
    Li S; Vriend LE; Nasser IA; Popov Y; Afdhal NH; Koziel MJ; Schuppan D; Exley MA; Alatrakchi N
    Hepatology; 2012 Dec; 56(6):2094-105. PubMed ID: 22806830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.
    Colmenero J; Bataller R; Sancho-Bru P; Domínguez M; Moreno M; Forns X; Bruguera M; Arroyo V; Brenner DA; Ginès P
    Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G726-34. PubMed ID: 19628656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 4 and hepatic fibrogenesis.
    Pradere JP; Troeger JS; Dapito DH; Mencin AA; Schwabe RF
    Semin Liver Dis; 2010 Aug; 30(3):232-44. PubMed ID: 20665376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of hepatic histopathology in kidney transplant recipients with chronic hepatitis C virus infection and effect of immunosuppression on the course of hepatitis C virus infection.
    Korkmaz M; Fakı S; Öcal S; Harmancı Ö; Selçuk H; Haberal M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():159-64. PubMed ID: 25894147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.